|
|
 |
|
Industry
Reports |
|
 |
|
|
HighTech Business Decisions currently has the following published
reports available: |
|
High Throughput
Screening 2007: New Strategies, Success Rates, and Use of
Enabling Technologies
This 980- page
report documents current HTS practices for drug discovery,
company organizations, and the evolving role of the HTS
laboratory in pharmaceutical companies, academic centers,
and institutes worldwide. This study provides an in-depth
analysis of the current levels of success as regards discovering
new drugs using HTS, evolving strategies to increase this
success, current and expected use of cell-based assays and
high content screening, detection technologies including
label-free detection, equipment used and purchases planned,
targets and target classes growing in importance, the number
of compounds screened, throughput, formats, budgets and
expenditures by product category, market size and expected
growth, and the challenges in HTS for both users and their
suppliers. Published December 2007.
>>Table of Contents >>
Order Form |
| |
|
| |
|
Biopharmaceutical Contract Manufacturing 2007:
Quality, Capacities and Emerging Technologies
This 800-page report, the comprehensive
2007 industry report, provides the latest information on biomanufacturing
strategies, new products and manufacturing efficiencies, expression
systems and cell lines, capacity additions, new equipment
including disposables, challenges ahead for the industry,
and expanded outsourcing services so readers can make the
most successful strategic decisions. The data and the analysis
in this report are based on 68 in-depth interviews conducted
with biomanufacturing directors at pharmaceutical and biotechnology
companies and contractor companies worldwide. It is the most
comprehensive and current industry report on biopharmaceutical
contract manufacturing. Published February 2007.
>> Table of Contents >>
Order Form
|
| |
|
|
|
Biopharmaceutical Contract Manufacturing:
Best Practices Pricing Study 2006
This 350-page report
documents pricing practices, policies, agreements, and strategies.
Learn what pharmaceutical and biotechnology companies are
paying contractors for mammalian cell culture, microbial
fermentation production, & related services. Understand
how contractors handle reservation fees, pricing algorithms,
failed batches, down payments, cancellation fees, process
development fees, technology transfer, IP, and other difficult-to-negotiate
issues.
>>
Table of Contents
>>
Order Form
|
|
|
|
|
The History of High Throughput Screening for Drug Discovery: 1998-2005
HighTech Business
Decisions (HTBD) has conducted six market research studies
and published six comprehensive industry reports on high
throughput screening (HTS) since 1998. This report is specifically
designed to understand the changes that have occurred in
HTS since 1998, how accurate HTS directors have been in
forecasting and predicting their use of technology and future
needs, how HTS practices have evolved, and the success of
HTS as a drug discovery tool. Topics include the number
of disease targets screened, target types, assay types,
detection modes, microplate formats, outsourcing, and other
issues impacting HTS operations and success. The complete
analysis, based on both user and supplier primary research,
includes market size and growth, major players, user strategies
and requirements, documentation of success in drug discovery,
trends and technologies, and respondents’ perceptions
regarding the future of HTS.
>>Table of Contents >>
Order Form |
|
|
|
|
2007 Directory of Biopharmaceutical Contract Manufacturers
Contract manufacturing services
for biopharmaceutical production are increasingly in demand
as a consequence of numerous biotechnology products in the
pipeline and changes in FDA regulations. The directory provides
a thorough listing of 79contractors worldwide, including information
on Type of Services Offered, Equipment Capacity, cGMP Certification
by Service Category and more.
>>Table of Contents >>
Order Form
|
|
|
|
|
|
 |
|
|
|
|
